Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Processa Pharmaceuticals Inc PCSA

Healthcare Biotechnology
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC... see more

Recent & Breaking News (NDAQ:PCSA)

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

GlobeNewswire March 23, 2023

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

GlobeNewswire March 17, 2023

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 7, 2023

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

GlobeNewswire February 21, 2023

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

GlobeNewswire February 15, 2023

Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

GlobeNewswire February 10, 2023

Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.

GlobeNewswire January 4, 2023

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

GlobeNewswire December 14, 2022

Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2022

PCS12852 Improves Gastric Emptying in Gastroparesis Patients

GlobeNewswire November 8, 2022

Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST

GlobeNewswire November 2, 2022

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

GlobeNewswire November 1, 2022

Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs

GlobeNewswire September 15, 2022

Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022

GlobeNewswire September 7, 2022

Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board

GlobeNewswire August 16, 2022

Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2022

Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST

GlobeNewswire August 5, 2022

Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

GlobeNewswire August 4, 2022

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

GlobeNewswire August 3, 2022

Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022

GlobeNewswire July 12, 2022